Arena and Ildong receive marketing authorization for obesity drug Belviq in South Korea
US biopharma company Arena Pharmaceuticals (Nasdaq: ARNA) has received marketing authorization in South Korea for Belviq (lorcaserin HCl) via its marketing and distribution partner, Ildong.
Belviq can now be marketed as a weight management drug in South Korea. Arena has a marketing and supply agreement with Ildong through Arena’s wholly-owned subsidiary Arena Pharmaceuticals GmbH, which will now receive a milestone payment of $3 million from Ildong.
Jack Lief, Arena’s president and chief executive, said: "We are pleased with this achievement, and continue to work with our collaborators to obtain approval for Belviq in additional territories. As a leading pharmaceutical company in South Korea with significant experience marketing obesity products, we are confident in Ildong's ability to make this novel therapy available to patients in South Korea."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze